T24 Orthotopic Mouse Model Service for Bladder Cancer

The T24 orthotopic mouse model stands as a cornerstone xenograft platform for dissecting the intrinsic biology of human bladder cancer, preserving the anatomical context, extracellular matrix architecture, and three-dimensional growth dynamics that define urothelial malignancy. Alfa Cytology brings deep technical proficiency to the establishment and deployment of this human-derived orthotopic system, offering investigators a meticulously controlled environment in which to profile drug sensitivity, map metastatic trajectories, and interrogate human-specific signaling networks prior to advancing candidates into downstream development pipelines.

Overview of T24 Orthotopic Mouse Model for Bladder Cancer

The T24 cell line was originally isolated in 1973 from a high-grade transitional cell carcinoma of the urinary bladder in a female patient, and it has since become one of the most extensively characterized human bladder cancer lines across molecular profiling panels. Genomically, T24 harbors an activating HRAS mutation (G12V) alongside a TP53 missense alteration and TERT promoter mutation, placing it within the genomically stable subgroup of urothelial carcinomas despite its Grade 3 histology. When introduced orthotopically into the bladder wall of immunodeficient hosts—most commonly athymic nude mice—T24 cells recapitulate the layered architecture of human bladder cancer progression, from superficial mucosal seeding through lamina propria invasion to eventual muscularis propria penetration. The model demands immunocompromised recipients because the human origin of T24 cells precludes growth in immunocompetent murine strains, yet this constraint simultaneously allows unencumbered evaluation of human tumor cell-autonomous behaviors and human-specific therapeutic targets without confounding species-mismatched immune responses.

Fig 1. In vivo efficacy of LBP treatment in nude mouse models of T24 and 5637 tumour xenografts. (Yu, Qian, et al., 2023)

Orthotopic implantation of T24 cells into the murine bladder lumen, typically following mechanical or chemical mucosal preconditioning, yields robust tumor engraftment with documented muscle-invasive progression and occasional distal dissemination to abdominal viscera. Unlike subcutaneous xenografts, the orthotopic configuration preserves the peritumoral stromal milieu, basement membrane interactions, and vascular supply patterns characteristic of human bladder cancer, thereby enhancing the translational fidelity of pharmacodynamic readouts. The model has proven particularly valuable for screening conventional chemotherapeutics such as cisplatin and gemcitabine, testing intravesical agents, and validating molecularly targeted compounds directed against human oncogenic drivers—making it an indispensable tool for investigators seeking preclinical evidence rooted in authentic human tumor biology.

Cell Line Information: T24

T24 is a human bladder transitional cell carcinoma cell line originally derived from a Grade 3 invasive tumor in a female patient. The line exhibits classic epithelial morphology in culture and demonstrates high proliferative capacity both in vitro and in immunodeficient hosts. Molecular characterization places T24 among the most frequently profiled bladder cancer cell lines, with data available across the Cancer Cell Line Encyclopedia (CCLE), Genomics of Drug Sensitivity in Cancer (GDSC), The Cancer Proteome Atlas (TCPA), and other comprehensive panels. The line carries hallmark oncogenic mutations in HRAS and TP53, coupled with TERT promoter activation, rendering it a representative model for studying MAPK pathway-driven bladder carcinogenesis and stress-response signaling. Notably, T24 is FGFR3 wild-type, distinguishing it from the FGFR3-mutant molecular subtype and aligning it more closely with the basal/squamous-like transcriptional subgroup of muscle-invasive bladder cancer.

Our Services

Alfa Cytology offers a comprehensive T24 orthotopic model service spanning authenticated cell banking, mucosal preconditioning optimization, surgical implantation, longitudinal tumor monitoring, and detailed endpoint characterization. Our preclinical team works closely with sponsors to align model parameters—such as host strain selection, cell inoculum density, and treatment scheduling—with the specific pharmacological questions under investigation, ensuring that every study generates actionable, publication-quality data under fully documented, GLP-compliant workflows.

Workflow of T24 Orthotopic Mouse Model Construction

Construction of the T24 orthotopic bladder cancer model at Alfa Cytology follows a harmonized protocol optimized for consistent tumor engraftment and physiologically relevant disease progression. The workflow integrates stringent cell quality assurance, refined transurethral surgical techniques, and systematic in vivo monitoring, all conducted under institutional animal care oversight. Below is the stepwise breakdown of model development from cell preparation through terminal analysis.

1. Cell Line Authentication and Expansion: T24 cells are revived from authenticated, mycoplasma-negative master cell banks and expanded under standard culture conditions. Prior to implantation, STR profiling is performed to confirm identity and rule out cross-contamination, while viability assessment by trypan blue exclusion ensures a live cell fraction exceeding 90%.
2. Host Selection and Acclimation: Female athymic nude mice (Balb/c nu/nu) or NOD-SCID mice, 6–8 weeks of age, are obtained from accredited vendors and acclimated for a minimum of 5–7 days under SPF housing. Baseline body weights and general health parameters are recorded, and animals are randomized into experimental cohorts using weight-based stratification.
3. Bladder Mucosal Preconditioning: To disrupt the protective urothelial barrier and promote tumor cell adhesion, the bladder mucosa is preconditioned immediately prior to cell instillation. Techniques include brief exposure to prewarmed 0.25% trypsin, dilute acid, or controlled mechanical abrasion via a modified catheter stylet, with the specific method selected based on pilot data and study objectives.
4. Orthotopic T24 Cell Instillation: Under inhalation anesthesia, a lubricated 24-gauge catheter is inserted transurethrally into the bladder, and residual urine is manually expressed. A single-cell suspension of 1.0–3.0 × 10⁶ T24 cells in 50–100 µl of serum-free medium is slowly instilled. The urethral meatus is gently occluded with a microvascular clamp or surgical clip for 60–90 minutes to retain the inoculum, after which the clamp is released and spontaneous voiding is confirmed.
5. Post-Procedure Recovery and Monitoring: Animals are transferred to a heated recovery chamber and monitored until fully ambulatory. Post-operative analgesia is administered according to IACUC guidelines. Daily health observations track body weight, hydration status, urination patterns, and signs of urinary obstruction or systemic distress, with predefined humane endpoints triggering immediate euthanasia if exceeded.
6. Tumor Establishment Monitoring: Tumor growth is assessed beginning approximately 7–10 days post-implantation through a combination of palpation, ultrasound biomicroscopy, or bioluminescence imaging (if luciferase-transduced T24 derivatives are employed). Imaging schedules are customized to the study design, capturing tumor establishment kinetics and enabling stratification into treatment arms at uniform baseline burdens.
7. Therapeutic Intervention: Upon confirmation of measurable tumor establishment, mice are randomized into vehicle control and treatment groups. Test compounds are administered via the route specified in the protocol—intravesical instillation, intraperitoneal injection, intravenous infusion, or oral gavage—according to predefined dosing regimens and pharmacokinetic considerations.
8. Longitudinal Assessment and Endpoint Analysis: Throughout the treatment phase, tumor response is monitored through serial imaging, body weight tracking, and clinical observation. At study termination, animals are humanely euthanized and subjected to comprehensive necropsy. Bladders are excised, weighed, and processed for H&E staining to evaluate tumor grade, invasion depth, and muscle layer involvement. Distant organs are examined histologically for metastatic foci, and supplementary analyses—including immunohistochemistry, TUNEL staining, or gene expression profiling—are performed as per the study plan.

Fig 2. T24 Orthotopic Mouse Model construction workflow.

Case Study-T24 Orthotopic Mouse Model Development

In a recent preclinical program, T24 cells were orthotopically implanted into immunodeficient mice following standardized mucosal preconditioning, yielding consistent tumor engraftment within the anticipated timeframe. Following establishment, animals were allocated to cohorts receiving either vehicle control or an investigational therapeutic agent, with dosing initiated once tumors achieved a predefined size threshold. Serial monitoring revealed differential growth kinetics between treatment and control groups, and terminal histopathological evaluation confirmed variance in tumor burden, depth of muscularis invasion, and stromal desmoplastic response. Ancillary molecular analyses provided mechanistic insight into target engagement and pathway modulation, generating a dataset suitable for supporting downstream candidate prioritization and regulatory discussions. All procedures were confined to preclinical evaluation under approved animal use protocols.

Why Choose Alfa Cytology?

Selecting Alfa Cytology as your preclinical partner for T24 orthotopic bladder cancer studies means leveraging a specialized infrastructure built around the unique demands of human xenograft oncology research. Our operational and scientific capabilities are designed to de-risk your program and accelerate the generation of robust, decision-ready datasets.

• Proven expertise in human bladder cancer xenograft models, with optimized protocols that achieve high tumor take rates and reproducible muscle-invasive progression in immunodeficient hosts.
• Rigorous cell line stewardship including STR authentication, mycoplasma screening, and batch-to-batch consistency checks to safeguard data integrity and eliminate contamination risk.
• Flexible host strain options—athymic nude, NOD-SCID, or NSG mice—matched to the immunological requirements and tumor growth characteristics of your specific study design.
• Integrated imaging capabilities spanning high-frequency ultrasound, bioluminescence, and magnetic resonance imaging for non-invasive, quantitative tumor monitoring throughout the study duration.
• Customizable treatment paradigms supporting intravesical, systemic, and combination dosing schedules with flexible sampling timepoints and biomarker collection windows.
• Comprehensive histopathology suite offering H&E, special stains, multiplex immunofluorescence, and digital pathology quantification to characterize tumor morphology, invasion, and therapeutic response.
• Streamlined project execution with dedicated study directors, transparent milestone reporting, and regulatory-compliant documentation packages tailored to IND-enabling and publication needs.

Contact Us

If your research program demands a human-relevant bladder cancer model with documented muscle-invasive progression and the flexibility to evaluate both conventional and targeted therapeutic modalities, we encourage you to reach out to us to discuss your specific requirements. The Alfa Cytology scientific team is prepared to design a customized T24 orthotopic study aligned with your compound's mechanism of action and development milestones. Contact us today to receive a detailed proposal and timeline for your upcoming preclinical bladder cancer program.

For research use only. Not intended for any clinical use.